ARAUJO, P. M. A. G.; http://lattes.cnpq.br/0844236806064113; ARAÚJO, Pascally Maria Aparecida Guerra de.
Resumo:
In this research, we propose, obtain and characterize in an unprecedented way
hybrid compounds (new drug carriers) the base on hydroxyapatite and nanoparticles
associated with tetraethylorthosilicate (TEOS) and the silane agent type 3-
aminopropyltrimethoxysilane (APTS) conjugated to the drug ciproflonax and evaluate
the effect of treatment osteomyelitis. In a first step, the individual materials
synthesized were. In the second stage, hybrids and hybrid composites obtained were
in different concentrations. The precursor materials and carriers obtained in steps I
and II characterized were by structural, morphological and magnetic analysis
techniques aiming at understanding the properties in the formation of the drug
delivery. The results of steps I and II indicated that the Fe3O4 magnetic nanoparticles
(NPM’s) were successfully obtained by microwave oven and CoFe2O4 combustion
reaction in a pilot scale scale reaction; The monophasic hydroxyapatite (HAp)
obtained by the precipitation method and NPM's@SiO2 hybrids (core-shell). In step II
the hybrid composites (magnetic drug delivery) were the base of the hybrid NPMs
and the commercial HAp of JHS Biomaterials and synthesized in the laboratory, with
crystalline and nanostructural characteristics. In that both the precursors obtained in
step I and the hybrid composites showed promising structural, morphological and
magnetic properties for use as a drug delivery specifically in the treatment of
osteomyelitis. In stage III the in vitro cytotoxicity assays were performed for the
hybrid precursors and composites obtained and drug release tests for the hybrid
composites (carriers). The Fe3O4, CoFe2O4 NPM’s of the Fe3O4@SiO2 and CoFe2O4
@SiO2 hybrids and the hydroxyapatite (HAp) synthesized in LaBSmaC were shown
to have cell viability greater than 70% and that the NPM’s coating of Fe3O4, CoFe2O4
and hybrid uptake have further increased cell viability and biocompatibility of
magnetic NPM’s as carriers of the drug ciprofloxacin. The biocompatibility of the
hybrid composites (drug delivery) and of the PVA solvent used for carrier dispersion
evaluated were at various concentrations via in vitro (cytotoxicity) studies. It observed
was by the cytotoxic profile that the safe concentration, in which the cell viability was
higher than 70%, was 0.312 mg/mL for the hybrid composites (carriers) HFeFS1,
HFeFS2, HCoFS1, HJCoFS1, F, e de 0,156 mg/mL para o compósito
HCoFS1.composite. Drug release tests, for the hybrid (carrier) composites confirmed
that, both Fe3O4@SiO2 and CoFe2O4@SiO2 carriers presented high efficiency in the
conjugation and release of the drug ciprofloxacin. However, the hybrid composites
synthesized with CoFe2O4 and the commercial HAp from JHS Biomaterials,
presented faster release when compared to hybrid composites formed with Fe3O4
and HAp synthesized in the laboratory. All these characteristics allowed helping in
the understanding of the properties of the studied materials for that these are
optimized efficiently for the development of a technological product, efficient for
application in the treatment of osteomyelitis.